Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)-Reference-Cited by-同舟云学术

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Published:2019-05 Issue:5 Volume:6 Page:e254-e265
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Morschhauser Franck,Flinn Ian W,Advani Ranjana,Sehn Laurie H,Diefenbach Catherine,Kolibaba Kathryn,Press Oliver W,Salles Gilles,Tilly Hervé,Chen Andy I,Assouline Sarit,Cheson Bruce D,Dreyling Martin,Hagenbeek Anton,Zinzani Pier Luigi,Jones Surai,Cheng Ji,Lu Dan,Penuel Elicia,Hirata Jamie,Wenger Michael,Chu Yu-Waye,Sharman Jeff

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

2. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;Hematology Am Soc Hematol Educ Program,2011

3. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma;Dang;Br J Haematol,2018

4. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial;Mounier;Haematologica,2011

5. Halwani AS, Rasmussen KM, Patil V, et al. Treatment practices and outcomes in older adults with relapsed/refractory diffuse large B-cell lymphoma treated in the Veterans Health Administration. Poster presented at American Society of Hematology—60th Annual Meeting; San Diego, CA, USA; Dec 1–4, 2018.

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system;Scientific Reports;2024-09-13

2. Analysis of histologic, immunohistochemical and genomic features of large B cell lymphoma tumors may predict response to polatuzumab vedotin based therapy in patients with relapsed/refractory disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Recent advances in CD5+ diffuse large B-cell lymphoma;Annals of Hematology;2024-08-28

4. Current and future therapies for follicular lymphoma;Experimental Hematology & Oncology;2024-08-22

5. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study;The Lancet;2024-07